CytoDyn Statistics
Total Valuation
CytoDyn has a market cap or net worth of 336.10 million. The enterprise value is 354.08 million.
| Market Cap | 336.10M |
| Enterprise Value | 354.08M |
Important Dates
The next estimated earnings date is Tuesday, January 13, 2026.
| Earnings Date | Jan 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CytoDyn has 1.26 billion shares outstanding. The number of shares has increased by 20.81% in one year.
| Current Share Class | 1.26B |
| Shares Outstanding | 1.26B |
| Shares Change (YoY) | +20.81% |
| Shares Change (QoQ) | +1.07% |
| Owned by Insiders (%) | 0.06% |
| Owned by Institutions (%) | 0.03% |
| Float | 1.26B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -3.38 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -15.73 |
| EV / Sales | n/a |
| EV / EBITDA | 47.98 |
| EV / EBIT | 48.74 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.19
| Current Ratio | 0.19 |
| Quick Ratio | 0.13 |
| Debt / Equity | n/a |
| Debt / EBITDA | 3.70 |
| Debt / FCF | n/a |
| Interest Coverage | 1.71 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 21.88% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -12.99% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.73M |
| Employee Count | 13 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +73.55% in the last 52 weeks. The beta is 1.37, so CytoDyn's price volatility has been higher than the market average.
| Beta (5Y) | 1.37 |
| 52-Week Price Change | +73.55% |
| 50-Day Moving Average | 0.28 |
| 200-Day Moving Average | 0.27 |
| Relative Strength Index (RSI) | 43.62 |
| Average Volume (20 Days) | 1,784,263 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 19.50 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | 7.26M |
| Pretax Income | -21.02M |
| Net Income | -22.51M |
| EBITDA | 7.28M |
| EBIT | 7.26M |
| Earnings Per Share (EPS) | -0.02 |
Balance Sheet
The company has 9.33 million in cash and 27.31 million in debt, giving a net cash position of -17.97 million or -0.01 per share.
| Cash & Cash Equivalents | 9.33M |
| Total Debt | 27.31M |
| Net Cash | -17.97M |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | -99.51M |
| Book Value Per Share | -0.08 |
| Working Capital | -56.07M |
Cash Flow
| Operating Cash Flow | -16.66M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CytoDyn does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.81% |
| Shareholder Yield | -20.81% |
| Earnings Yield | -6.70% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |